These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23007025)

  • 21. Effect of an L-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial.
    Bonomini M; Di Liberato L; Del Rosso G; Stingone A; Marinangeli G; Consoli A; Bertoli S; De Vecchi A; Bosi E; Russo R; Corciulo R; Gesualdo L; Giorgino F; Cerasoli P; Di Castelnuovo A; Monaco MP; Shockley T; Rossi C; Arduini A
    Am J Kidney Dis; 2013 Nov; 62(5):929-38. PubMed ID: 23725973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acid-base profile and predictors of metabolic acidosis in patients undergoing peritoneal dialysis with lactate- and bicarbonate-buffered peritoneal dialysis solutions.
    Fourtounas C; Savidaki E; Roumelioti M; Dousdampanis P; Hardalias A; Kalliakmani P; Papachristou E; Drakopoulos A; Goumenos DS; Vlachojannis JG
    Adv Perit Dial; 2006; 22():187-91. PubMed ID: 16983967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.
    Yoon HE; Chang YK; Shin SJ; Choi BS; Kim BS; Park CW; Song HC; Yoon SA; Jin DC; Kim YS
    J Korean Med Sci; 2014 Sep; 29(9):1217-25. PubMed ID: 25246739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study).
    Kim SG; Kim S; Hwang YH; Kim K; Oh JE; Chung W; Oh KH; Kim HJ; Ahn C;
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S117-22. PubMed ID: 18552239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exfoliated mesothelial cell and CA-125 in automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD) patients.
    Kanjanabuch T; Puttipittayathorn N; Leelahavanichkul A; Lieusuwan S; Katavetin P; Mahatanan N; Sriudom K; Chirananthavat T; Thongbor N; Eiam-Ong S
    J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S119-25. PubMed ID: 22043578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The
    Htay H; Cho Y; Pascoe EM; Darssan D; Hawley C; Johnson DW;
    Perit Dial Int; 2017; 37(3):283-289. PubMed ID: 27935537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraperitoneal interleukin-6 levels predict peritoneal solute transport rate: a prospective cohort study.
    Yang X; Zhang H; Hang Y; Yan H; Lin A; Huang J; Ni Z; Qian J; Fang W
    Am J Nephrol; 2014; 39(6):459-65. PubMed ID: 24854010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
    Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
    J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.
    Wang AY; Wang M; Woo J; Lam CW; Lui SF; Li PK; Sanderson JE
    J Am Soc Nephrol; 2004 Aug; 15(8):2186-94. PubMed ID: 15284304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetic Modeling of Incremental Ambulatory Peritoneal Dialysis Exchanges.
    Guest S; Leypoldt JK; Cassin M; Schreiber M
    Perit Dial Int; 2017; 37(2):205-211. PubMed ID: 28096442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
    Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
    Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Factors for Decline of Residual Renal Function in Children Treated With Peritoneal Dialysis.
    Roszkowska-Blaim M; Skrzypczyk P
    Perit Dial Int; 2016 11-12; 36(6):669-675. PubMed ID: 27605680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of patient survival in continuous ambulatory peritoneal dialysis: 10-year experience in 2 major centers in Tehran.
    Hakemi MS; Golbabaei M; Nassiri A; Kayedi M; Hosseini M; Atabak S; Ganji MR; Amini M; Saddadi F; Najafi I
    Iran J Kidney Dis; 2010 Jan; 4(1):44-9. PubMed ID: 20081304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Residual renal function and volume control in peritoneal dialysis patients.
    Cheng LT; Chen W; Tang W; Wang T
    Nephron Clin Pract; 2006; 104(1):c47-54. PubMed ID: 16741370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
    Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors.
    Lang SM; Bergner A; Töpfer M; Schiffl H
    Perit Dial Int; 2001; 21(1):52-7. PubMed ID: 11280496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Importance of residual renal function in continuous ambulatory peritoneal dialysis: its influence on different parameters of renal replacement treatment.
    López-Menchero R; Miguel A; García-Ramón R; Pérez-Contreras J; Girbés V
    Nephron; 1999; 83(3):219-25. PubMed ID: 10529628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
    Rodrigues AS; Martins M; Korevaar JC; Silva S; Oliveira JC; Cabrita A; Castro e Melo J; Krediet RT
    Am J Nephrol; 2007; 27(1):84-91. PubMed ID: 17284895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term increase of glucose concentration in PDS results in extensive removal and high glycation level of vital proteins during continuous ambulatory peritoneal dialysis.
    Pešić I; Dihazi GH; Müller GA; Jahn O; Hoffmann M; Eltoweissy M; Koziolek M; Dihazi H
    Nephrol Dial Transplant; 2011 Aug; 26(8):2674-83. PubMed ID: 21285129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.